Literature DB >> 30221045

Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5'-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients.

Timo J Vogt1, Heidrun Gevensleben2, Jörn Dietrich1, Glen Kristiansen2, Friedrich Bootz1, Jennifer Landsberg3, Diane Goltz4, Dimo Dietrich1.   

Abstract

Background: The adenosine A2a receptor (A2aR) and the adenosine synthesizing enzyme CD73 have recently evolved as a novel immunotherapeutic target. However, little is known about epigenetic modification of the encoding genes ADORA2A and NT5E.
Methods: In the present study, we evaluated methylation at 23 loci of ADORA2A and 17 loci of NT5E with regard to transcriptional activity, human papilloma virus (HPV) status, immune cell infiltration, and outcome in a cohort of 279 head and neck squamous carcinoma (HNSCC) patients obtained from The Cancer Genome Atlas (TCGA). Methylation and mRNA expression were generated by the Infinium HumanMethylation450 BeadChip and Illumina HiSeq 2000 RNA Sequencing Version 2 analysis (Illumina, Inc., San Diego, CA, USA). HPV status was assessed by RNA-Seq data analysis of the viral genes E6 and E7.
Results: Thirteen out of 23 ADORA2A loci and 15/17 NT5E loci were significantly correlated with mRNA levels (p < 0.05). Inverse correlations were predominately found in promoter regions, while positive correlations were more profound at intragenic loci. ADORA2A hypermethylation was significantly associated with poor overall survival (OS, p ≤ 0.030), whereas NT5E hypomethylation was associated with decreased OS in HPV-positive tumors (p ≤ 0.024) and increased OS in HPV-negative HNSCC (p ≤ 0.029). Further, we found significant correlations between methylation and immune cell infiltrates.
Conclusion: Our data might point towards a significant role of the A2aR/CD73 axis during cancer progression in HNSCC.

Entities:  

Keywords:  ADORA2A; Adenosine A2a Receptor; Biomarker; CD73; DNA Methylation; HPV; Head and Neck Squamous Cell Carcinoma; Immunotherapy; NT5E; Prognosis

Year:  2018        PMID: 30221045      PMCID: PMC6136855          DOI: 10.1080/2162402X.2018.1452579

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  39 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Age-associated DNA methylation changes in naive CD4+ T cells suggest an evolving autoimmune epigenotype in aging T cells.

Authors:  Mikhail G Dozmorov; Patrick Coit; Kathleen Maksimowicz-McKinnon; Amr H Sawalha
Journal:  Epigenomics       Date:  2017-03-21       Impact factor: 4.778

3.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Authors:  Tanguy Y Seiwert; Barbara Burtness; Ranee Mehra; Jared Weiss; Raanan Berger; Joseph Paul Eder; Karl Heath; Terrill McClanahan; Jared Lunceford; Christine Gause; Jonathan D Cheng; Laura Q Chow
Journal:  Lancet Oncol       Date:  2016-05-27       Impact factor: 41.316

Review 4.  Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

Authors:  Scott J Antonia; Johan F Vansteenkiste; Edmund Moon
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

5.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

Review 6.  Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

Authors:  V Kumar
Journal:  Purinergic Signal       Date:  2012-12-28       Impact factor: 3.765

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma.

Authors:  Matthias Lechner; Tim Fenton; James West; Gareth Wilson; Andrew Feber; Stephen Henderson; Christina Thirlwell; Harpreet K Dibra; Amrita Jay; Lee Butcher; Ankur R Chakravarthy; Fiona Gratrix; Nirali Patel; Francis Vaz; Paul O'Flynn; Nicholas Kalavrezos; Andrew E Teschendorff; Chris Boshoff; Stephan Beck
Journal:  Genome Med       Date:  2013-02-05       Impact factor: 11.117

9.  Conversion of T cells to B cells by inactivation of polycomb-mediated epigenetic suppression of the B-lineage program.

Authors:  Tomokatsu Ikawa; Kyoko Masuda; Takaho A Endo; Mitsuhiro Endo; Kyoichi Isono; Yoko Koseki; Rinako Nakagawa; Kohei Kometani; Junichiro Takano; Yasutoshi Agata; Yoshimoto Katsura; Tomohiro Kurosaki; Miguel Vidal; Haruhiko Koseki; Hiroshi Kawamoto
Journal:  Genes Dev       Date:  2016-12-02       Impact factor: 11.361

10.  Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.

Authors:  Si-Rui Ma; Wei-Wei Deng; Jian-Feng Liu; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Mol Cancer       Date:  2017-06-07       Impact factor: 27.401

View more
  7 in total

1.  CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Junyun Lai; Amanda X Y Chen; Deborah Meyran; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Christina Mølck; Gregory D Stewart; Benjamin J Solomon; Ian A Parish; Paul J Neeson; Simon J Harrison; Lev M Kats; Imran G House; Phillip K Darcy; Paul A Beavis
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

2.  A potential prognostic model based on miRNA expression profile in The Cancer Genome Atlas for bladder cancer patients.

Authors:  Yan Liu; Dong Yan Zhu; Hong Jian Xing; Yi Hou; Yan Sun
Journal:  J Biol Res (Thessalon)       Date:  2020-05-19       Impact factor: 1.889

3.  NT5E is associated with unfavorable prognosis and regulates cell proliferation and motility in gastric cancer.

Authors:  Sifeng Hu; Fanmei Meng; Xiankun Yin; Changling Cao; Guangyong Zhang
Journal:  Biosci Rep       Date:  2019-05-17       Impact factor: 3.840

Review 4.  Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Authors:  Kevin Sek; Christina Mølck; Gregory D Stewart; Lev Kats; Phillip K Darcy; Paul A Beavis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

Review 5.  CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.

Authors:  Haitang Yang; Feng Yao; Paul F Davis; Swee T Tan; Sean R R Hall
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

Review 6.  IFN-γ and CD38 in Hyperprogressive Cancer Development.

Authors:  Stefania Angelicola; Francesca Ruzzi; Lorena Landuzzi; Laura Scalambra; Francesco Gelsomino; Andrea Ardizzoni; Patrizia Nanni; Pier-Luigi Lollini; Arianna Palladini
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

7.  Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.

Authors:  Siqi Chen; Ping Xie; Matthew Cowan; Hao Huang; Horacio Cardenas; Russell Keathley; Edward J Tanner; Gini F Fleming; John W Moroney; Alok Pant; Azza M Akasha; Ramana V Davuluri; Masha Kocherginsky; Bin Zhang; Daniela Matei
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.